Lutetium Lu-177
- Generic Name
- Lutetium Lu-177
- Brand Names
- Lutathera, Lumark, EndolucinBeta, Lutetium (177Lu) chloride Billev (previously Illuzyce)
- Drug Type
- Small Molecule
- Chemical Formula
- Lu
- CAS Number
- 14265-75-9
- Unique Ingredient Identifier
- BRH40Y9V1Q
- Associated Conditions
- Neuroendocrine Tumors
- Associated Therapies
- -
Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland
Completed
- Conditions
- Interventions
- First Posted Date
- 2023-01-26
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1
- Registration Number
- NCT05701007
- Locations
- 🇫🇮
Pfizer, Helsinki, Finland
Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine Tumors
Phase 1
Active, not recruiting
- Conditions
- Interventions
- First Posted Date
- 2022-02-21
- Last Posted Date
- 2024-01-25
- Lead Sponsor
- Providence Health & Services
- Target Recruit Count
- 6
- Registration Number
- NCT05249114
- Locations
- 🇺🇸
Providence Portland Cancer Institute - Franz Clinic, Portland, Oregon, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath